Advantages of Treatment of Hypertension with Minoxidil

1980 ◽  
Vol 25 (2) ◽  
pp. 99-103
Author(s):  
C. Isles ◽  
R. W. Strachan

A detailed study has been made of the five hypertensive patients who received Minoxidil in Dumfries; four have been observed for over a year. Minoxidil was found to be highly effective, free from commonly encountered side effects and capable of achieving excellent control of blood pressure when given once daily. Its use led to simpler drug regimens, improved compliance and significant reduction in the length, or even need, of admission to hospital. A prolonged and clinically useful delay in the recurrence of hypertension following withdrawal of the drug was also observed.

1979 ◽  
Vol 7 (3) ◽  
pp. 201-214 ◽  
Author(s):  
P G Baker ◽  
J Goulton

A three-month open, multicentre trial was carried out in 2132 hypertensive patients under uncontrolled conditions in general practice, to assess the effectiveness and tolerance of acebutolol when given orally as a single morning dose, in the range of 200 to 1200 mg/day. Concomitant antihypertensive therapy was given to 702 patients. Forty-five patients, out of 1893 who were eligible for analysis, showed inadequate blood pressure control and were withdrawn from the study. There were 602 reports of side-effects or adverse reactions attributed to acebutolol in 584 patients, necessitating 120 withdrawals from the trial. The results showed that acebutolol given once daily produces a substantial and progressive reduction in blood pressure over the three months of the trial. The changes from pre-trial values of all haemodynamic assessments measured were statistically significant (p < 0-001).


1976 ◽  
Vol 4 (5) ◽  
pp. 347-351 ◽  
Author(s):  
A M Harris ◽  
K V Woollard ◽  
J A Tweed

A clinical study is described in which hypertensive patients on no drug therapy were given atenolol in increasing doses from 50 mg twice daily to 200 mg twice daily until the diastolic blood pressure was 90 mm Hg or below. At this stage the drug was withdrawn until blood pressure readings had risen to pre-treatment levels. The same dose of atenolol was then re-introduced but now given once-a-day (in the morning) and was continued for four weeks. Of the eleven patients entering the study, one withdrew as his blood pressure was not controlled on a dose of 200 mg of atenolol twice daily, and another because on withdrawal of atenolol his blood pressure did not rise to pre-treatment levels. The remaining nine patients completed the study. There was a statistically significant fall in blood pressure on both atenolol regimes and there was no significant difference between the blood pressure control achieved on twice-a-day and once-a-day administration. Only one patient developed side-effects; this being an asthmatic who developed mild dyspnoea on atenolol which did not necessitate withdrawal of the drug. It is concluded that once-a-day administration of a given dose of atenolol is therapeutically equivalent to twice-a-day administration. The implications of this in terms of better patient compliance, and thus better prognosis, are discussed.


1989 ◽  
Vol 17 (1) ◽  
pp. 76-81
Author(s):  
R. Fariello ◽  
E. Boni ◽  
C. Alicandri ◽  
A. Zaninelli ◽  
A. Cantalamessa ◽  
...  

Vasodilator drugs reduce peripheral vascular resistance but lead to a secondary baroreflex-mediated chronotropic effect. After angiotensin-converting enzyme inhibition, blood pressure falls without associated tachycardia. In a previous study it was observed that enalapril increased vagal tone in essential hypertensive patients. In order to evaluate the effect of enalapril on sympathetic stimulation 10 mild to moderate hypertensive patients were studied during static (hand grip) and dynamic exercise (bicycle ergometer), after 2 weeks of placebo and after 1 month of treatment with 20–40 mg enalapril once daily. Enalapril significantly reduced blood pressure and the rate–pressure product at rest and at peak dynamic exercise. There was no effect on supine and maximal heart rate. Enalapril also significantly reduced blood pressure during hand grip, but did not interfere with the rate of the increase. Thus, enalapril does not seem to interfere with sympathetic adaptation to stress.


1986 ◽  
Vol 64 (6) ◽  
pp. 770-771
Author(s):  
Frans H. H. Leenen

In recent years antihypertensive therapy has evolved from treatment for a relatively small number of patients with severe hypertension to treatment for millions of people with mild to severe hypertension. We now treat not only patients at high risk for future cardiovascular morbidity and mortality, of whom nearly all are benefitting from antihypertensive therapy, but also much larger groups of patients each individually at low risk. In this latter group only a small percentage actually benefits from antihypertensive therapy. For example, in the Australian trial in subjects with mild hypertension and no other evidence of cardiovascular disease, only two excess deaths were prevented at the expense of 1000 patient-years of drug treatment (Australian Therapeutic Trial 1980). For most individual members of this group normalizing their mild blood pressure elevation appears to offer no benefit, yet all of them are exposed to antihypertensive therapy and its side effects. When instituting antihypertensive pharmacotherapy in patients with mild hypertension one has to be concerned about these side effects, not just the objective ones (e.g., effects on plasma lipoproteins or glucose which may offset any gains to be obtained by lowering blood pressure), but also subjective ones (e.g., fatigue, impotence) which may markedly affect the quality of life.Nonpharmacologic, in particular nutritional, management of mild hypertension has intuitively major appeal for "lowering blood pressure without side effects." Many studies have evaluated the effects of dietary changes on blood pressure. Several recent symposia have addressed the issue of nutrition and hypertension. Despite this, the report from the first Consensus Development Conference of the Canadian Hypertension Society ("on the management of mild hypertension in Canada") states "Because of conflicting evidence and problems with patient compliance, the conference had difficulty reaching consensus on the effectiveness of salt restriction and, for the obese, of weight reduction in lowering blood pressure" (Logan 1984).This issue of the Canadian Journal of Physiology and Pharmacology contains the proceedings of a workshop "Nutritional Management of Hypertension: Controversies and Frontiers," held in Harrison Hot Springs, British Columbia, September 6–7, 1985. This workshop was organized under the auspices of the Canadian Hypertension Society and made possible by generous financial support from ICI Pharma, Canada (general sponsorship) as well as from the National Institute of Nutrition for the obesity session, and from the Dairy Bureau of Canada for the sodium–calcium session.To define more clearly the controversies and uncertainties, this workshop was organized in a different way than previous meetings dealing with this issue. A clinical scientist working in a particular area was invited to outline the evidence in favour of a given dietary manipulation for the treatment of hypertension, and another one to outline the evidence against. This evaluation would particularly concern evidence regarding "efficacy" and "effectiveness". A discussant then presented an evaluation of the two position papers, followed by a general discussion and a summary by the session chairman. This type of scrutiny of our current knowledge was done for sodium restriction, calcium supplementation, and weight loss. As part of this evaluation two speakers addressed the closely related issues of practical aspects of diet management (e.g. compliance) and the consequences–risks of weight loss in relation to the pathophysiology of obesity.In the last part of the workshop possible future developments in nutrition and hypertension were reviewed, such as "nutrition in the young, early intervention?," vegetarian approach to hypertension, role of dietary fats, and proteins and precursors.The organizing committee very much appreciated that Dr. David Sackett was willing to serve as the scientific chairman of this workshop, to summarize the present "state of the art" on diet modulation in the management of hypertension as well as to propose recommendations for treatment of hypertension in clinical practice and for future research directions.It was a pleasure for me to serve as chairman of the organizing committee. As President of the Canadian Hypertension Society I would like to thank all session chairmen, speakers, discussants, and participants for their enthusiasm and eagerness to explore the topic of nutrition and hypertension. I hope that the scientific information and insight that the proceedings of this workshop offer will convey their commitment.


1978 ◽  
Vol 55 (s4) ◽  
pp. 353s-354s
Author(s):  
A. Jouve ◽  
L. Goldet ◽  
M. Mathieu

1. 10 294 hypertensive patients were treated and followed by 2200 general practitioners under the supervision of 130 cardiologists and nephrologists. 2. The treatment groups, randomly allocated, were designated to use three distinct antihypertensive drugs, administered alone, and combined two-by-two. 3. Some 75% of patients had a supine diastolic blood pressure of less than 95 mmHg after 4 months treatment. 4. A total of 12% of patients had dropped out by 4 months from entry; no clear relationship was established between side effects and drop out.


Author(s):  
Toting Ardhiansyah ◽  
Sukadiono Sukadiono ◽  
Suyatno H S ◽  
Muhammad Anas

Background: Hypertension is linearly associated with cardiovascular disease morbidity and mortality. Therefore, hypertension must be prevented and treated, and controlled adequately. Early treatment of hypertension is crucial because it can prevent complications in several organs such as the heart, kidneys, and brain. The treatment of hypertension has shifted from pharmacology to non-pharmacology because of the side effects it causes. One of the non-pharmacological management for hypertensive patients is slow deep breathing exercises. The mechanism of slow deep breathing relaxation (slow deep breathing) in the respiratory system is in the form of a state of inspiration and exhalation with a frequency of breaths of 6-10 times per minute, resulting in an increase in a cardiopulmonary stretch.Objective: To determine the effect of relaxation therapy: slow deep breathing on lowering blood pressure in patients with grade 1 hypertension.Method: Pre-experimental Design One Group Pre-Post Test Design.Results: Before being given slow deep breathing relaxation therapy, patients with grade 1 hypertension had an average (mean) systolic and diastolic blood pressure of 152.16 and 93.68 mmHg. After being given slow deep breathing relaxation therapy, patients with grade 1 hypertension have an average (mean) systolic and diastolic blood pressure of 140.42 and 92.74 mmHg.Conclusion: There is a significant effect between Relaxation Therapy: Slow Deep Breathing on Decreasing Blood Pressure in Level 1 Hypertension Patients.


1989 ◽  
Vol 17 (2) ◽  
pp. 113-124
Author(s):  
S. Di Somma ◽  
S. Savonitto ◽  
M. Petitto ◽  
V. Liguori ◽  
C. Magnotta ◽  
...  

The effect of therapy with atenolol and tocainide, separately or in combination, was studied in 20 patients with hypertension and concomitant ventricular arrhythmias. Patients were given 400 mg tocainide, three times daily, 100 mg atenolol, once daily (plus 25 mg hydrochlorothiazide and 2.5 mg amiloride diuretics if required) and a combination of these treatments. Tocainide alone significantly reduced the incidence of ventricular arrhythmias without affecting atrial arrhythmias. It also controlled exercise-induced arrhythmias in 7/13 (54%) patients. Atenolol significantly reduced atrial arrhythmias and had a good effect on exercise-induced arrhythmias (reduced in 75% of patients), but it did not have a significant effect on ventricular arrhythmias. In 13 patients, despite normalization of blood pressure by atenolol, it was necessary to combine antihypertensive therapy (atenolol) with anti-arrhythmic therapy (tocainide) in order to reduce ventricular arrhythmias. All drugs were well tolerated. It is concluded that, in certain patients, specific anti-arrhythmic treatment may be necessary to control ventricular arrhythmias in hypertensive patients despite normalization of blood pressure by β-blockers.


1976 ◽  
Vol 51 (s3) ◽  
pp. 567s-570s
Author(s):  
B. N. C. Prichard ◽  
A. J. Boakes ◽  
B. R. Graham

1. A within-patient comparison showed that bethanidine, methyldopa and propranolol produced similar control of the blood pressure. 2. Unlike bethanidine, propranolol did not produce postural and exercise hypotension; methyldopa was intermediate in effect. 3. Overall side effects were of a similar incidence though there were differences in incidence of particular side effects.


1974 ◽  
Vol 48 (s2) ◽  
pp. 181s-184s ◽  
Author(s):  
M. Fernandes ◽  
I. Sanford Smith ◽  
A. Weder ◽  
K. E. Kim ◽  
Anne B. Gould ◽  
...  

1. Prazosin decreases blood pressure in normotensive, renal hypertensive and spontaneous hypertensive rats. The effect is greatest in the last-named. 2. In spontaneously hypertensive rats the decrease in pressure is associated with a decrease in heart rate. 3. In hypertensive patients prazosin decreases blood pressure by decreasing total peripheral resistance with minor effects on cardiac output. 4. Prazosin is effective in the long-term therapy of hypertensive patients, alone and in combination with a diuretic. The effect on blood pressure is the same in the supine and standing position.


Sign in / Sign up

Export Citation Format

Share Document